AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7948436
Drug: Low-dose surfactant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose surfactant treatment (100 mg/kg)
Trial: 29277607
Drug: Mastic oleoresin
RxNorm normalized name: Capsicum Oleoresin
DrugBank: Capsicum oleoresin (DB11131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastic oleoresin (MO), 15g administered for three days through smoking the episiotomy wound
Trial: 29277607
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no MO treatment)
Trial: 21738098
Drug: Pain clinic
RxNorm normalized name: Stopain Clinical
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain clinic (PC) evaluation with or without treatment
Trial: 18458035
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo cream) with nitrous oxide/oxygen
Trial: 8564129
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg rhDNase aerosol, twice a day for six consecutive days
Trial: 2021379
Drug: Multi-component behavioral
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component behavioral treatment package (IBD education, progressive muscle relaxation, thermal biofeedback, cognitive coping strategies)
Trial: 2021379
Drug: Multi-component behavioral
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component behavioral treatment package
Trial: 29679478
Drug: bleselumab (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleselumab (0.1, 0.3, 1.0 or 3.0 mg/kg)
Trial: 29679478
Drug: bleselumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleselumab (1.0 or 3.0 mg/kg)
Trial: 28662313
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CRT) with concurrent cisplatin followed by adjuvant cisplatin plus fluorouracil
Trial: 26197975
Drug: Monosodium glutamate
RxNorm normalized name: Monosodium Glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monosodium glutamate (MSG) ingestion (150 mg/kg)
Trial: 26197975
Drug: Glutamate (Glu)
RxNorm normalized name: glutamate
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Glutamate (Glu) injection (0.5 M, 0.2 ml)
Trial: 26197975
Drug: NaCl (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (placebo) injection (0.9%, 0.2 ml)
Trial: 26197975
Drug: Pre-injection MSG
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-injection MSG ingestion
Trial: 26197975
Drug: Glu injections
RxNorm normalized name: Glu
DrugBank: gamma-Glutamylcysteine (DB03408)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glu injections into the masseter muscle
Trial: 26197975
Drug: MSG ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSG ingestion and Glu injection in the jaw muscles
Trial: 21921953
Drug: Ologen (OLO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ologen (OLO) implant
Trial: 21921953
Drug: Low-dosage mitomycin-C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage mitomycin-C (MMC)
Trial: 1988521
Drug: 6-monthly dosing
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-monthly dosing
Trial: 1988521
Drug: Yearly dosing
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yearly dosing (12 and 24 months after initial therapy)
Trial: 6346588
Drug: Intradermal jet
RxNorm normalized name: Jet Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal jet injector
Trial: 6346588
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection (half a million units)
Trial: 3566845
Drug: Lisuride (Dopergin)
RxNorm normalized name: lisuride
DrugBank: Lisuride (DB00589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisuride (Dopergin) - average dosage 1 mg/d
Trial: 3566845
Drug: Bromocriptine -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine - average dosage 10 mg/d
Trial: 27577069
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus sunitinib (n=24)
Trial: 27577069
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (n=25)
Trial: 25008857
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg Mg/d (oral magnesium supplementation)
Trial: 20398561
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/d for 8 weeks
Trial: 10695183
Drug: Fixed Dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed Dose Combination (FDC) of rifampicin (RIF) and isoniazid (INH)
Trial: 10695183
Drug: Separate formulation
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate formulation of rifampicin (RIF)
Trial: 10695183
Drug: Imported FDC
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imported FDC formulation of rifampicin (RIF) and isoniazid (INH)
Trial: 6849741
Drug: Indoramin 50
RxNorm normalized name: indoramin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin 50 mg
Trial: 1685666
Drug: Disopyramide 150
RxNorm normalized name: disopyramide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disopyramide 150 mg
Trial: 6759334
Drug: Cefroxadine 1
RxNorm normalized name: cefroxadine
DrugBank: Cefroxadine (DB11367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefroxadine 1 g t.i.d. for five days
Trial: 6759334
Drug: Cephalexin 1
RxNorm normalized name: cephalexin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin 1 g t.i.d. for five days
Trial: 30596666
Drug: Cotrimoxazole 960
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole 960 mg/tablet (CTX group)
Trial: 30596666
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral placebo (PLC group)
Trial: 21691746
Drug: Bosutinib 200-600
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200-600 mg with food
Trial: 21691746
Drug: Bosutinib 200
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200 mg with food
Trial: 21691746
Drug: Bosutinib 400
RxNorm normalized name: bosutinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 400 mg with food
Trial: 21691746
Drug: Bosutinib 200-800
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200-800 mg with food
Trial: 21691746
Drug: Bosutinib 200-800
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib 200-800 mg
Trial: 17572803
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous sulfate (40 mg once weekly)
Trial: 17572803
Drug: Iron bis-glycinate
RxNorm normalized name: prenatal vitamin no.86/iron bis-glycinate/folic acid 32 mg-1,000 mcg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron bis-glycinate chelate-enriched cookies (3.8 mg, 3x/week for 8 weeks)
Trial: 17572803
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions for children with depleted iron stores (< 15 ng/mL)
Trial: 9263281
Drug: Glutamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (30 g/d, divided in 3 doses of 10 g each) for 8 consecutive days during each interval between chemotherapy
Trial: 8214727
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (75-micrograms bolus and infusion of 2.5 micrograms/mL at 15 mL/h)
Trial: 8214727
Drug: Ultra low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ultra low-dose bupivacaine (0.04%), epinephrine (1.7 micrograms/mL), and fentanyl (1.7 micrograms/mL) (15-mL bolus followed by infusion at 15 mL/h)
Trial: 2962088
Drug: Human hemi-synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human hemi-synthetic insulin
Trial: 2962088
Drug: Porcine MC-insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine MC-insulin
Trial: 31328671
Drug: Robot therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot therapy (RT) for 60 minutes
Trial: 25770784
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for relatives of people with mental health problems
Trial: 16524789
Drug: Original omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Original omeprazole (10 mg once daily after breakfast)
Trial: 16524789
Drug: Omeprazole-Towa (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole-Towa (10 mg once daily after breakfast)
Trial: 16524789
Drug: Omerap (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omerap (10 mg once daily after breakfast)
Trial: 16524789
Drug: Omeprazon (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazon (10 mg once daily after breakfast)
Trial: 16524789
Drug: Ovulanze (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulanze (10 mg once daily after breakfast)
Trial: 9499939
Drug: Road traffic
RxNorm normalized name: Road to Wellness KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Road traffic noise of 75 dBA for 15 min with 0.25 mg of alprazolam (Xanax®) ingested 1 hr before
Trial: 9499939
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg of alprazolam (Xanax®) without noise exposure
Trial: 2831701
Drug: Delta-9-THC (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta-9-THC (doses of 2.5-15 mg)
Trial: 27933161
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid (ICS) and leukotriene-receptor antagonist (LTRA)
Trial: 18622483
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine solution
Trial: 10704956
Drug: Intravenous glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glycine (100 mg/kg or 200 mg/kg)
Trial: 10704956
Drug: Oral D-cycloserine
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-cycloserine (50 mg)
Trial: 10704956
Drug: Intravenous glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous glycine
Trial: 10704956
Drug: Oral D-cycloserine
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral D-cycloserine
Trial: 8167297
Drug: Large-scale therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-scale therapeutic trials of agents intended to alter outcome
Trial: 4616803
Drug: Flavoxate (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavoxate (600 mg daily)
Trial: 15526107
Drug: Carteolol 20
RxNorm normalized name: carteolol 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol 20 mg/day for 7 days
Trial: 15526107
Drug: Carteolol (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carteolol (20, 40 or 80 mg p.o.)
Trial: 15526107
Drug: Bisoprolol (beta(1)-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (beta(1)-adrenoceptor blocker)
Trial: 7720769
Drug: 3% dorzolamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% dorzolamide, approximately 7.7 micrograms per day (21.3 mumol) dorzolamide hydrochloride, administered bilaterally q.i.d. for 14 days
Trial: 7720769
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered bilaterally q.i.d. for 14 days
Trial: 7720769
Drug: Acetazolamide, 125
RxNorm normalized name: AcetaZOLAMIDE, 125 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide, 125 mg q.i.d.
Trial: 1904333
Drug: Pravastatin 5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 5, 10, 20, 40 mg
Trial: 6118074
Drug: ORG NC45
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG NC45 0.1 mg/kg
Trial: 6118074
Drug: ORG NC45
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG NC45 0.15 mg/kg
Trial: 23788751
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day plus erlotinib 150 mg/day
Trial: 23788751
Drug: Erlotinib 150
RxNorm normalized name: erlotinib 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day (placebo plus erlotinib)
Trial: 19668882
Drug: Diphereline 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphereline 3.75 mg, 4 times every 28 days (group I)
Trial: 19668882
Drug: Cabergoline 0.5
RxNorm normalized name: cabergoline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5 mg, once a week for 6 weeks (group II)
Trial: 15514287
Drug: Lithium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium dose of 250 micromol Li
Trial: 15514287
Drug: Lithium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium dose of 213 micromol Li
Trial: 15514287
Drug: Lithium dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium dose of 175 micromol Li
Trial: 15514287
Drug: Measuring serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measuring serum Li 3-9 h after the last dose
Trial: 11176734
Drug: Zanamivir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (10 mg twice daily for 5 days)
Trial: 9779135
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (100 ml 10% NaCl)
Trial: 8286206
Drug: IL-2 plus
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2)
Trial: 3051530
Drug: Aspirin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (50 mg/day, adjusted up to 100 mg/day)
Trial: 26139202
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + T-614 (50 mg/day for 24 weeks)
Trial: 26139202
Drug: MTX (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX (10 mg/week for first 4 weeks, then 12.5 mg/week for 20 weeks)
Trial: 17382417
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum digoxin concentrations (0.5-0.9 ng/ml)
Trial: 14520775
Drug: 18% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18% carbamide peroxide gel (Colgate Simply White) applied twice daily
Trial: 9365358
Drug: Subacromial local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial local anesthetic injection
Trial: 27871575
Drug: Alfentanil 55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 55 μg/kg
Trial: 27871575
Drug: Alfentanil doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil doses (0, 10, 20, 30, 40, 50, and 60 μg/kg)
Trial: 27871575
Drug: Alfentanil (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (various doses)
Trial: 22775448
Drug: Weekly Swedish
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly Swedish massage
Trial: 22775448
Drug: Twice-weekly Swedish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly Swedish massage
Trial: 18201457
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TA) 100 mg
Trial: 18201457
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (TA) 1 g
Trial: 18201457
Drug: Combined results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined results from TA groups (100 mg and 1 g)
Trial: 18201457
Drug: Topical epsilon‐aminocaproic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical epsilon‐aminocaproic acid (EACA)
Trial: 9816716
Drug: Mivacurium (non-priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (non-priming group, n = 20) - 0.25 mg/kg as a single intubating dose
Trial: 9816716
Drug: Mivacurium (priming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mivacurium (priming group, n = 20) - 0.225 mg/kg preceded by 0.025 mg/kg 3 min earlier
Trial: 9816716
Drug: Succinylcholine (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine (control group, n = 20) - 1 mg/kg as an intubating bolus
Trial: 2700113
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day mepindolol (Group A)
Trial: 2700113
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day metoprolol duriles (Group B)
Trial: 2700113
Drug: Both beta-blockers
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both beta-blockers (mepindolol and metoprolol)
Trial: 29460812
Drug: Black tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black tea (∼400 mg flavonoids, equivalent to 2-3 cups of tea)
Trial: 27241836
Drug: Acute aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute aspirin supplementation
Trial: 27241836
Drug: Chronic aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic aspirin supplementation
Trial: 21405957
Drug: Allopurinol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (150 mg daily for 8 weeks) with ACE-I (perindopril)
Trial: 21405957
Drug: Allopurinol (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (150 mg daily for 8 weeks) with thiazide (hydrochlorothiazide)
Trial: 18626522
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg premedication
Trial: 14610410
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg bicalutamide
Trial: 11212479
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid cream applied in nostrils, 20 mg/gm, twice a day for four weeks
Trial: 9104518
Drug: Group 1A
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1A (portal injections with lidocaine, intraarticular lidocaine, placebo femoral nerve block)
Trial: 9104518
Drug: Group FNB
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group FNB (femoral 3-in-1 nerve block with chloroprocaine, placebo portal injections, placebo intraarticular saline)
Trial: 9104518
Drug: Group FNB
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group FNB + IA (femoral 3-in-1 nerve block, intraarticular lidocaine, placebo portal injections)
Trial: 3549871
Drug: CNS stimulants
RxNorm normalized name: CNS STIMULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS stimulants (methylphenidate)
Trial: 30002346
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy (WBC) treatment after exercise (-140 °C, 3 min)
Trial: 30002346
Drug: Whole-body cryotherapy
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body cryotherapy (WBC) treatment after exercise
Trial: 26400901
Drug: Steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection (SI)
Trial: 22265921
Drug: NT‐proBNP >1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP >1800 pg/mL
Trial: 22265921
Drug: NT‐proBNP <150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT‐proBNP <150 pg/mL
Trial: 19720489
Drug: Single-dose gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose gadobutrol (0.1 mmol/kg b.w.)